Skip to content

Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery

Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00366444
Enrollment
201
Registered
2006-08-21
Start date
2006-08-31
Completion date
Unknown
Last updated
2011-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Postoperative

Keywords

Bunionectomy, Bunion surgery, Post-operative pain

Brief summary

A multicenter study to evaluate the analgesic efficacy of XP21L in subjects with pain following bunionectomy surgery.

Interventions

25 mg every 6 hours

DRUGPlacebo

Placebo every 6 hours

Sponsors

Xanodyne Pharmaceuticals
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* 18-65 years of age * Have undergone bunionectomy surgery * Have achieved adequate post-surgical pain

Exclusion criteria

* Confounding medical conditions which preclude study participation * Participated in a study of another investigational drug or device within 30 days prior to randomization

Design outcomes

Primary

MeasureTime frameDescription
Average Numeric Pain Rating Score (NPRS) Over 48 Hours After BunionectomyOver 48 hours after bunionectomyPain intensity scores were measured using an 11-point numerical pain rating scale (NPRS) with 0=no pain to 10=worst possible pain

Secondary

MeasureTime frameDescription
Number of Patients With at Least 30% Reduction in Pain Intensity After First Dose of Study Drug8 hours post single dose
Time to Onset of at Least 30% Reduction in Pain Intensity After First Dose of Study Drug8 hours post single dose
Number of Patients With Perceptible Pain Relief on Day 18 hours post single doseTimes to onset of Perceptible and Meaningful Relief were determined using the double-stopwatch method.
Median Time to Onset of Pain Relief in Patients With Perceptible Pain Relief on Day 18 hours post single dose
Number of Patients Who Required Rescue Medication on Day 1Day 1
Median Time to Onset of Pain Relief in Patients With Meaningful Pain Relief on Day 18 hours post single dose
Total Pain Relief (TOTPAR) Scores 8 Hours Post Initial Dose of Study Drug8 hours post single dosePain relief was rated using a 5-point categorial scale (0=none, 1=a little, 2=some, 3=a lot, and 4=complete) at time of dose (time=0) and over 15 time points afterwards (10, 15, 20, 30, 45, and 60 minutes and at 1.5, 2, 2.5, 3, 4, 5, 6, 7, and 8 hours after the initial dose on Day 1 or until time of re-medication). A score of 0 across all time points would be the lowest (worst) and a score of 60 (4 X 15 time points) would be the highest (best) possible score.
Number of Patients Who Required Rescue Medication on Day 2Day 2
Number of Patients Who Required Rescue Medication on Day 3Day 3Day 3 data reflect the use of rescue medication only up to the time of discharge
Number of Patients With Meaningful Pain Relief on Day 18 hours post single doseTimes to onset of Perceptible and Meaningful Relief were determined using the double-stopwatch method.

Countries

United States

Participant flow

Participants by arm

ArmCount
Zipsor (Diclofenac Potassium) Liquid Filled Capsule
25 mg capsule, every 6 hours
102
Placebo
Oral placebo capsule, every 6 hours
99
Total201

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyLack of Efficacy01
Overall StudyWithdrawal by Subject11

Baseline characteristics

CharacteristicZipsor (Diclofenac Potassium) Liquid Filled CapsulePlaceboTotal
Age Continuous45 years
STANDARD_DEVIATION 11
45 years
STANDARD_DEVIATION 12
45 years
STANDARD_DEVIATION 11.5
Baseline pain score6.9 units on a scale
STANDARD_DEVIATION 1.7
7.3 units on a scale
STANDARD_DEVIATION 1.9
7.1 units on a scale
STANDARD_DEVIATION 1.8
Race/Ethnicity, Customized
Asian
4 participants5 participants9 participants
Race/Ethnicity, Customized
Black
23 participants19 participants42 participants
Race/Ethnicity, Customized
Caucasian
61 participants56 participants117 participants
Race/Ethnicity, Customized
Hispanic
13 participants16 participants29 participants
Race/Ethnicity, Customized
Other
1 participants3 participants4 participants
Region of Enrollment
United States
102 participants99 participants201 participants
Sex: Female, Male
Female
88 Participants86 Participants174 Participants
Sex: Female, Male
Male
14 Participants13 Participants27 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
21 / 10244 / 99
serious
Total, serious adverse events
0 / 1021 / 99

Outcome results

Primary

Average Numeric Pain Rating Score (NPRS) Over 48 Hours After Bunionectomy

Pain intensity scores were measured using an 11-point numerical pain rating scale (NPRS) with 0=no pain to 10=worst possible pain

Time frame: Over 48 hours after bunionectomy

ArmMeasureValue (MEAN)Dispersion
Zipsor (Diclofenac Potassium) Liquid Filled CapsuleAverage Numeric Pain Rating Score (NPRS) Over 48 Hours After Bunionectomy2.5 units on a scaleStandard Deviation 2
PlaceboAverage Numeric Pain Rating Score (NPRS) Over 48 Hours After Bunionectomy5.6 units on a scaleStandard Deviation 2
Secondary

Median Time to Onset of Pain Relief in Patients With Meaningful Pain Relief on Day 1

Time frame: 8 hours post single dose

Population: Number of participants analyzed includes only the number of participants with meaningful pain relief on Day 1 (see previous outcome measure, #4).~Number of patients in the placebo group is intentionally blank as the data was not calculable since less than 50% of the patients reported meaningful relief (ie, median cannot be calculated).

ArmMeasureValue (MEDIAN)
Zipsor (Diclofenac Potassium) Liquid Filled CapsuleMedian Time to Onset of Pain Relief in Patients With Meaningful Pain Relief on Day 170.2 minutes
Secondary

Median Time to Onset of Pain Relief in Patients With Perceptible Pain Relief on Day 1

Time frame: 8 hours post single dose

Population: Number of participants analyzed includes only the number of participants with perceptible pain relief on Day 1 (see previous Outcome Measure #2)

ArmMeasureValue (MEDIAN)
Zipsor (Diclofenac Potassium) Liquid Filled CapsuleMedian Time to Onset of Pain Relief in Patients With Perceptible Pain Relief on Day 126.0 minutes
PlaceboMedian Time to Onset of Pain Relief in Patients With Perceptible Pain Relief on Day 122.2 minutes
Secondary

Number of Patients Who Required Rescue Medication on Day 1

Time frame: Day 1

ArmMeasureValue (NUMBER)
Zipsor (Diclofenac Potassium) Liquid Filled CapsuleNumber of Patients Who Required Rescue Medication on Day 140 participants
PlaceboNumber of Patients Who Required Rescue Medication on Day 187 participants
Secondary

Number of Patients Who Required Rescue Medication on Day 2

Time frame: Day 2

ArmMeasureValue (NUMBER)
Zipsor (Diclofenac Potassium) Liquid Filled CapsuleNumber of Patients Who Required Rescue Medication on Day 222 participants
PlaceboNumber of Patients Who Required Rescue Medication on Day 264 participants
Secondary

Number of Patients Who Required Rescue Medication on Day 3

Day 3 data reflect the use of rescue medication only up to the time of discharge

Time frame: Day 3

ArmMeasureValue (NUMBER)
Zipsor (Diclofenac Potassium) Liquid Filled CapsuleNumber of Patients Who Required Rescue Medication on Day 35 participants
PlaceboNumber of Patients Who Required Rescue Medication on Day 329 participants
Secondary

Number of Patients With at Least 30% Reduction in Pain Intensity After First Dose of Study Drug

Time frame: 8 hours post single dose

ArmMeasureValue (NUMBER)
Zipsor (Diclofenac Potassium) Liquid Filled CapsuleNumber of Patients With at Least 30% Reduction in Pain Intensity After First Dose of Study Drug62 participants
PlaceboNumber of Patients With at Least 30% Reduction in Pain Intensity After First Dose of Study Drug40 participants
Secondary

Number of Patients With Meaningful Pain Relief on Day 1

Times to onset of Perceptible and Meaningful Relief were determined using the double-stopwatch method.

Time frame: 8 hours post single dose

ArmMeasureValue (NUMBER)
Zipsor (Diclofenac Potassium) Liquid Filled CapsuleNumber of Patients With Meaningful Pain Relief on Day 158 participants
PlaceboNumber of Patients With Meaningful Pain Relief on Day 135 participants
Secondary

Number of Patients With Perceptible Pain Relief on Day 1

Times to onset of Perceptible and Meaningful Relief were determined using the double-stopwatch method.

Time frame: 8 hours post single dose

ArmMeasureValue (NUMBER)
Zipsor (Diclofenac Potassium) Liquid Filled CapsuleNumber of Patients With Perceptible Pain Relief on Day 184 participants
PlaceboNumber of Patients With Perceptible Pain Relief on Day 169 participants
Secondary

Time to Onset of at Least 30% Reduction in Pain Intensity After First Dose of Study Drug

Time frame: 8 hours post single dose

Population: Number of participants analyzed includes only the number of participants with at least a 30% reduction in pain intensity after the 1st dose (see previous outcome measure, #7).~Number of placebo patients is intentionally blank as the data (eg., upper CI) was not calculable.

ArmMeasureValue (MEDIAN)
Zipsor (Diclofenac Potassium) Liquid Filled CapsuleTime to Onset of at Least 30% Reduction in Pain Intensity After First Dose of Study Drug60 minutes
Secondary

Total Pain Relief (TOTPAR) Scores 8 Hours Post Initial Dose of Study Drug

Pain relief was rated using a 5-point categorial scale (0=none, 1=a little, 2=some, 3=a lot, and 4=complete) at time of dose (time=0) and over 15 time points afterwards (10, 15, 20, 30, 45, and 60 minutes and at 1.5, 2, 2.5, 3, 4, 5, 6, 7, and 8 hours after the initial dose on Day 1 or until time of re-medication). A score of 0 across all time points would be the lowest (worst) and a score of 60 (4 X 15 time points) would be the highest (best) possible score.

Time frame: 8 hours post single dose

ArmMeasureValue (MEAN)Dispersion
Zipsor (Diclofenac Potassium) Liquid Filled CapsuleTotal Pain Relief (TOTPAR) Scores 8 Hours Post Initial Dose of Study Drug8.2 units on a scaleStandard Deviation 9.3
PlaceboTotal Pain Relief (TOTPAR) Scores 8 Hours Post Initial Dose of Study Drug2.6 units on a scaleStandard Deviation 3.9

Source: ClinicalTrials.gov · Data processed: Apr 2, 2026